ACXP - CIK 0001736243
The table below shows Acurx Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$1.41M | -$2.05M | -$3.06M | -$1.93M | -$1.88M | -$547.14K |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
Acurx Pharmaceuticals, Inc. reported operating cash flow of -$6.79M for fiscal year 2025. That is up 34.6% from -$10.38M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$3.35M (FY 2020) to -$6.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.11M | $2.99M | $4.51M | - | - | - |